These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15180860)

  • 1. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
    Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
    Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mechanisms of AML1 gene alteration in hematological malignancies.
    Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
    Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
    Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
    Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
    Osato M
    Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
    Yergeau DA; Hetherington CJ; Wang Q; Zhang P; Sharpe AH; Binder M; Marín-Padilla M; Tenen DG; Speck NA; Zhang DE
    Nat Genet; 1997 Mar; 15(3):303-6. PubMed ID: 9054947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
    Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
    Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.
    Li XL; Arai Y; Harada H; Shima Y; Yoshida H; Rokudai S; Aikawa Y; Kimura A; Kitabayashi I
    Oncogene; 2007 Nov; 26(51):7231-9. PubMed ID: 17533375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional mutagenesis of AML1/RUNX1 and PEBP2 beta/CBF beta define distinct, non-overlapping sites for DNA recognition and heterodimerization by the Runt domain.
    Nagata T; Werner MH
    J Mol Biol; 2001 Apr; 308(2):191-203. PubMed ID: 11327761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early hematopoietic development.
    Fujita Y; Nishimura M; Taniwaki M; Abe T; Okuda T
    Biochem Biophys Res Commun; 2001 Mar; 281(5):1248-55. PubMed ID: 11243869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
    Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
    Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
    Song WJ; Sullivan MG; Legare RD; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende IC; Haworth C; Hock R; Loh M; Felix C; Roy DC; Busque L; Kurnit D; Willman C; Gewirtz AM; Speck NA; Bushweller JH; Li FP; Gardiner K; Poncz M; Maris JM; Gilliland DG
    Nat Genet; 1999 Oct; 23(2):166-75. PubMed ID: 10508512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML.
    Andersen MK; Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2005 Feb; 19(2):197-200. PubMed ID: 15618958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
    Peterson LF; Lo MC; Okumura AJ; Zhang DE
    Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.